Hosted on MSN1mon
Alpha Tau announces FDA approval of IDE supplement
FDA, of an Investigational Device Exemption IDE, supplement to the IDE previously announced on Jan 27, 2025, which had approved a clinical study examining the combination of Alpha DaRT and first ...
pharmaphorum4d
FDA’s review date for BMS’ ide-cel sneaks under the CVR wire
The FDA has given a 27 March 2021 review date for Bristol-Myers Squibb’s multiple myeloma cell therapy ide-cel, just in time to meet a contingent value right (CVR) due to Celgene shareholders if ...
Yahoo Finance1mon
Newronika Receives Investigational Device Exemption (IDE) from FDA to Initiate U.S. Clinical Trial of Adaptive DBS System
"Receiving an IDE from the FDA is a landmark achievement for Newronika," said Dr. Lorenzo Rossi, Co-Founder and CEO of Newronika. "It affirms the potential of our adaptive DBS system to fill an ...